Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Peptide Vaccines for Cancer

Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_4441-2

Definition

An immunogen composed of synthetic peptides (small protein sequences) administered with the intent of eliciting antitumor immune responses for treating cancer.

Characteristics

Principles of Antitumor Immunity

The immune system has the capacity to recognize tumor cells, and in many instances, this recognition results in antitumor effects such as slowing the tumor growth or tumor eradication. In view of this, many approaches have been made to develop cancer vaccines and other modes of immunotherapy. Cytotoxic T lymphocytes (CTLs) are considered the most effective elements of the immune system that can kill tumor cells. CTLs recognize small fragments (peptides of 8–10 residues) derived from the proteolytic processing of a tumor antigen. These peptides are presented to the CTL antigen receptor in the context of products of the class I major histocompatibility gene complex (MHC) known as HLA class Iin humans. Recognition of peptide/MHC class I complexes that are expressed on...

Keywords

Peptide Vaccine Major Histocompatibility Gene Complex Proinflammatory Signal Recognize Tumor Cell Antitumor Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access

References

  1. Berzofsky JA, Terabe M, Oh S et al (2004) Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 113:1515–1525CrossRefPubMedPubMedCentralGoogle Scholar
  2. Bruggen P, Van Der Zhang Y, Chaux P et al (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188:51–64CrossRefGoogle Scholar
  3. Burg SH, van der Bijker MS, Welters MJ et al (2006) Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Adv Drug Deliv Rev 58:916–930CrossRefPubMedGoogle Scholar
  4. Buteau C, Markovic SN, Celis E (2002) Challenges in the development of effective peptide vaccines for cancer. Mayo Clin Proc 77:339–349CrossRefPubMedGoogle Scholar
  5. Rammensee HG, Weinschenk T, Gouttefangeas C et al (2002) Towards patient-specific tumor antigen selection for vaccination. Immunol Rev 188:164–176CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Georgia Cancer CenterAugusta UniversityAugustaUSA